UnitedHealth Group (UNH) posted lower-than-expected earnings for the fourth quarter, driven by a significant increase in medical costs that outpaced premium growth. The results sparked concern across the healthcare and insurance sectors, with related stocks and volatility indicators reacting sharply.
- UNH's adjusted EPS fell 7% YoY in Q4 2025, missing estimates by 11%
- Medical costs rose 12.3% YoY to $78.9 billion, exceeding guidance
- Medical loss ratio increased to 88.7% in commercial segment
- UNH stock declined 4.7% after-hours; XLV dropped 2.3%
- CBOE Volatility Index (^VIX) rose 15% to 22.6
- Humana (HUM) and CVS Health (CVS) also reported margin pressures
UnitedHealth Group (UNH) reported a 7% decline in adjusted earnings per share for Q4 2025, falling short of analysts' expectations by 11%. The miss was primarily attributed to a 12.3% year-over-year surge in medical costs, which rose to $78.9 billion—well above the company's forecasted range of $74–75 billion. Despite 8.1% premium growth, the widening gap between cost and revenue pressured operating margins to 11.4%, down from 13.2% in the prior-year quarter. The unexpected inflation in healthcare expenses reflects broader sector-wide pressures, potentially signaling persistent medical inflation that could challenge insurers' pricing power. UnitedHealth’s commercial segment, which accounts for over 60% of total revenue, saw medical loss ratios climb to 88.7%, up from 85.1% in Q4 2024. This trend mirrors rising costs in other major health insurers, with Humana (HUM) and CVS Health (CVS) both reporting similar margin compression in recent earnings cycles. The market reacted swiftly: UNH stock dropped 4.7% in after-hours trading, while the S&P 500 Health Care Sector ETF (XLV) declined 2.3%. The CBOE Volatility Index (^VIX) spiked 15% to 22.6, indicating heightened investor anxiety over sector stability. Analysts are now revising forecasts for 2026, with several downgrading UNH and HUM on margin concerns. The results underscore the vulnerability of large insurers to unanticipated cost shocks, especially in a high-interest-rate environment where capital costs are elevated. As healthcare inflation remains sticky, investors are reassessing the sustainability of current pricing models across the insurance value chain.